AstraZeneca Pharma India Limited inaugurated a new 25,600 sq ft corporate office in Mumbai on October 16, 2026. The facility marks an extension of the company's presence in India, reinforcing its ambition to transform care by unlocking the power of science.

The new office was inaugurated by Maharashtra Chief Minister Devendra Fadnavis alongside senior government officials and embassy dignitaries. This strategic move aims to strengthen the company's ability to work with partners across the healthcare ecosystem and advance solutions for patients in India.

Expanding research and commercial footprint

AstraZeneca has introduced more than 25 new medicines and indications in India over the past three years. The company is currently running about 80 global clinical trials in the country. These efforts support the development of new treatments and strengthen India's contribution to global research.

Praveen Rao Akkinepally, Country President and Managing Director, stated that India is at an important inflection point in healthcare with a growing need for earlier diagnosis and innovative treatments. The company employs nearly 5,000 colleagues across the country.

Strategic focus on access and innovation

The organization focuses on pioneering newer access pathways so life-saving therapies reach every patient. Working closely with governments and industry, AstraZeneca leverages AI and builds solutions across the continuum of care, from prevention and awareness to diagnosis and treatment at scale.

This expansion supports closer engagement with stakeholders in therapy areas including Oncology, Biopharmaceuticals, and Rare Disease. It also facilitates continued investment in talent and capability building, creating opportunities for professionals passionate about transforming healthcare through science and technology.

What the numbers show

The establishment of this office correlates with significant operational scale in India. The presence of 80 global clinical trials alongside a workforce of 5,000 employees indicates that India serves as a critical hub for both R&D execution and commercial operations. The introduction of 25 new medicines in three years highlights a rapid portfolio expansion pace, suggesting strong regulatory and market entry capabilities within the region.

AstraZeneca Pharma India Limited has disclosed an Environmental, Social and Governance (ESG) rating of 73 for financial year 2025-26. The rating was assigned by NSE Sustainability Ratings and Analytics Limited.

The company filed this disclosure with BSE Limited and National Stock Exchange of India Limited on October 16, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that the rating agency did not engage with the company directly for this assessment.

Independent assessment methodology

NSE Sustainability Ratings and Analytics Limited prepared the report using publicly available information about the company. The agency operated independently, meaning the score reflects external analysis of existing disclosures rather than a collaborative audit or internal review process initiated by AstraZeneca Pharma India.

This distinction is critical for investors assessing the robustness of the governance framework. An independent rating based solely on public data tests the transparency and accessibility of the company’s reported metrics. A score of 73 suggests a moderate to strong performance across environmental, social, and governance criteria as interpreted by the agency’s proprietary model applied to open-source data.